In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).Listen as he gives his perspectives on the:PrEP pipeline and the importance of having options for patients with differing preferencesFDA approval of long-acting cabotegravir for PrEPHPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarateSafety data on long-acting cabotegravir for PrEPCDC recommendations on the management of injection-site reactions with cabotegravir for PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at:https://bit.ly/3tbvEPKSee the entire program at: https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related